Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.
Fischer L, Jiang L, Bittenbring JT, Huebel K, Schmidt C, Duell J, Metzner B, Krauter J, Glass B, Huettmann A, Schaefer-Eckart K, Silkenstedt E, Klapper W, Hiddemann W, Unterhalt M, Dreyling M, Hoster E; German Lymphoma Alliance (GLA) and the German Low-Grade Lymphoma Study Group (GLSG). Fischer L, et al. Among authors: silkenstedt e. Ann Hematol. 2023 Oct;102(10):2791-2801. doi: 10.1007/s00277-023-05385-1. Epub 2023 Aug 8. Ann Hematol. 2023. PMID: 37552322 Free PMC article.
[Aggressive lymphoma (DLBCL, MCL) - what's new?].
Silkenstedt E, Dreyling M. Silkenstedt E, et al. Dtsch Med Wochenschr. 2022 Nov;147(22):1449-1456. doi: 10.1055/a-1811-9691. Epub 2022 Nov 1. Dtsch Med Wochenschr. 2022. PMID: 36318907 German.
PARP14 is a novel target in STAT6 mutant follicular lymphoma.
Mentz M, Keay W, Strobl CD, Antoniolli M, Adolph L, Heide M, Lechner A, Haebe S, Osterode E, Kridel R, Ziegenhain C, Wange LE, Hildebrand JA, Shree T, Silkenstedt E, Staiger AM, Ott G, Horn H, Szczepanowski M, Richter J, Levy R, Rosenwald A, Enard W, Zimber-Strobl U, von Bergwelt-Baildon M, Hiddemann W, Klapper W, Schmidt-Supprian M, Rudelius M, Bararia D, Passerini V, Weigert O. Mentz M, et al. Among authors: silkenstedt e. Leukemia. 2022 Sep;36(9):2281-2292. doi: 10.1038/s41375-022-01641-x. Epub 2022 Jul 18. Leukemia. 2022. PMID: 35851155 Free PMC article.
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E, Arenas F, Colom-Sanmartí B, Xargay-Torrent S, Higashi M, Giró A, Rodriguez V, Fuentes P, Aulitzky WE, van der Kuip H, Beà S, Toribio ML, Campo E, López-Guerra M, Colomer D. Silkenstedt E, et al. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446. doi: 10.1186/s13046-019-1458-7. J Exp Clin Cancer Res. 2019. PMID: 31676012 Free PMC article.
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Fischer L, Jiang L, Dürig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, Trappe RU, Hallek M, Graeven U, Hänel M, Hoffmann M, Delwail V, Macro M, Greiner J, Giagounidis AAN, Dargel B, Durot E, Foussard C, Silkenstedt E, Weigert O, Pott C, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Ribrag V, Dreyling M. Fischer L, et al. Among authors: silkenstedt e. Leukemia. 2024 Apr 27. doi: 10.1038/s41375-024-02254-2. Online ahead of print. Leukemia. 2024. PMID: 38678093
12 results